Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

[Helicobacter pylori: comparative study of different diagnostic techniques].

Fazzio S, Vázquez G, Ardao G, Blanco J, Vivero E, Gualco G, Figari I, Velázquez S, Araujo E.

Acta Gastroenterol Latinoam. 1995;25(5):269-76. Spanish.

PMID:
8733252
2.

Towards an immunotherapy for p185HER2 overexpressing tumors.

Carter P, Rodrigues ML, Lewis GD, Figari I, Shalaby MR.

Adv Exp Med Biol. 1994;353:83-94. No abstract available.

PMID:
7985544
3.

Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor.

Tartaglia LA, Goeddel DV, Reynolds C, Figari IS, Weber RF, Fendly BM, Palladino MA Jr.

J Immunol. 1993 Nov 1;151(9):4637-41.

PMID:
8409424
4.
5.

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM.

Cancer Immunol Immunother. 1993 Sep;37(4):255-63.

PMID:
8102322
6.

Interventions for the treatment of septic shock.

Figari IS, Palladino MA.

Ann N Y Acad Sci. 1993 Jun 23;685:483-7. Review. No abstract available.

PMID:
8363257
7.

Multiple defects of immune cell function in mice with disrupted interferon-gamma genes.

Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA.

Science. 1993 Mar 19;259(5102):1739-42.

PMID:
8456300
8.

Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.

Ashkenazi A, Marsters SA, Capon DJ, Chamow SM, Figari IS, Pennica D, Goeddel DV, Palladino MA, Smith DH.

Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10535-9.

9.

The two different receptors for tumor necrosis factor mediate distinct cellular responses.

Tartaglia LA, Weber RF, Figari IS, Reynolds C, Palladino MA Jr, Goeddel DV.

Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):9292-6.

10.

Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.

Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, Figari I, Kotts CE, Palladino MA Jr, Ullrich A, et al.

J Clin Immunol. 1991 May;11(3):117-27. Review.

PMID:
1679763
11.

Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation.

Wu J, Palladino MA, Figari IS, Morris RE.

Transplant Proc. 1991 Feb;23(1 Pt 1):238-40. No abstract available.

PMID:
1703683
12.

TGF-beta: a possible autocrine immune regulator.

Lucas C, Wallick S, Fendly BM, Figari I, Palladino MA.

Ciba Found Symp. 1991;157:98-108; discussion 108-14.

PMID:
2070686
13.
14.

The autocrine production of transforming growth factor-beta 1 during lymphocyte activation. A study with a monoclonal antibody-based ELISA.

Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA.

J Immunol. 1990 Sep 1;145(5):1415-22.

PMID:
2384664
15.

The involvement of human tumor necrosis factors-alpha and -beta in the mixed lymphocyte reaction.

Shalaby MR, Espevik T, Rice GC, Ammann AJ, Figari IS, Ranges GE, Palladino MA Jr.

J Immunol. 1988 Jul 15;141(2):499-503.

PMID:
2968403
16.

In vivo anti-tumour activity of recombinant human tumour necrosis factor-alpha against Meth-A sarcoma requires L3T4-positive T cells.

Palladino MA, Figari IS.

Ann Inst Pasteur Immunol. 1988 May-Jun;139(3):299-301. No abstract available.

PMID:
2901845
18.

Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha.

Kramer SM, Aggarwal BB, Eessalu TE, McCabe SM, Ferraiolo BL, Figari IS, Palladino MA Jr.

Cancer Res. 1988 Feb 15;48(4):920-5.

19.
21.

Inhibition of cytokine production by cyclosporin A and transforming growth factor beta.

Espevik T, Figari IS, Shalaby MR, Lackides GA, Lewis GD, Shepard HM, Palladino MA Jr.

J Exp Med. 1987 Aug 1;166(2):571-6.

22.

Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.

Palladino MA Jr, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS, et al.

J Immunol. 1987 Jun 1;138(11):4023-32.

PMID:
3295044
23.

Possible relationships between in vivo antitumour activity and toxicity of tumour necrosis factor-alpha.

Palladino MA Jr, Patton JS, Figari IS, Shalaby MR.

Ciba Found Symp. 1987;131:21-38. Review.

PMID:
3330012
24.

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.

Dinarello CA, Cannon JG, Wolff SM, Bernheim HA, Beutler B, Cerami A, Figari IS, Palladino MA Jr, O'Connor JV.

J Exp Med. 1986 Jun 1;163(6):1433-50.

25.

Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr, Shepard HM.

Science. 1985 Nov 22;230(4728):943-5.

PMID:
3933111

Supplemental Content

Loading ...
Support Center